GlassScriptPhysician profile
Amy Sexton Harrell
NPI 1962827428
$2,419.73
in general payments reported to CMS, 2019-2025
22 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $638 · 2022: $436 · 2023: $635 · 2024: $379 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $349.14 | 2021-2025 | |
| Abbvie INC. | $323.33 | 2021-2025 | |
| Glaxosmithkline, LLC. | $314.81 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $176.42 | 2021-2025 | Ozempic, Wegovy |
| Amgen INC. | $175.57 | 2022-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $158.11 | 2022 | |
| Nevro Corp. | $146.98 | 2023 | Senza |
| Lilly USA, LLC | $110.82 | 2021-2024 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $106.04 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.93 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $90.01 | 2021-2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $72.37 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.60 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.83 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $45.06 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $34.29 | 2021 | |
| Phathom Pharmaceuticals, INC. | $23.27 | 2024 | Voquezna |
| Corcept Therapeutics | $21.54 | 2025 | Korlym |
| Philips North America LLC | $18.35 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Exact Sciences Corporation | $17.61 | 2023 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $15.43 | 2025 | Hetlioz, Fanapt |
| Mylan Specialty L.P. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.